Welcome to the ERACODA website
The European Renal Association COVID-19 Database is a European database collecting clinical information of patients on kidney replacement therapy with COVID-19.
The database currently (December 22, 2020) includes 2656 records on 2575 unique patients (72% dialysis patients and 28% kidney transplant recipients). Furthermore, follow-up data 3 months after COVID-19 diagnosis has been completed for 1174 patients and 102 centers have returned the ERACODA center questionnaire (79% of all active centers).
More than 200 clinicians representing approximately 130 centres from 31 countries (mostly in Europe and brodering the Mediterranean Sea) have contributed data to ERACODA.
The mission of ERACODA is to gain insight in what the COVID-19 epidemic means for patients treated with dialysis or a kidney transplantation across Europe, in the hope to improve their prognosis by intervening on modifiable risk factors.
The primary aim of ERACODA is to investigate the clinical course and outcomes (including hospital admission, intensive care admission and mortality) of patients on kidney replacement therapy with COVID-19. Such information may guide clinical treatment decisions and support triage strategies for admission to critical care units.
A secondary aim is to gain information on risk factors for mortality. Knowledge on modifiable patient and treatment characteristics associated with outcome may lead to interventions or changes in transplantation strategies that can improve prognosis.
What data are collected?
Data are collected from all outpatient and hospitalized adult patients (aged ≥18 years) with a functioning kidney allograft or on maintenance dialysis treatment who are diagnosed with COVID-19. This diagnosis needs to be based on a positive result on a real-time polymerase chain reaction (PCR) assay of nasal or pharyngeal swab specimens, and/or compatible findings on a CT scan or chest X-ray of the lungs.